Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption

Detalhes bibliográficos
Autor(a) principal: RIZELIO,Vanessa
Data de Publicação: 2019
Outros Autores: MACUCO,Andre Luiz Borba, SATO,Henry Koiti, NASCIMENTO,Maria Tereza de Moraes Souza, SOUZA,Ricardo Krause Martinez de, KOWACS,Pedro André
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000700456
Resumo: ABSTRACT Patients on anticoagulant or antiplatelet therapy are often required to discontinue these medications before and during surgical or invasive procedures. In some cases, the patient stops the treatment without medical supervision. These situations may increase stroke risk. Objective To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil. Methods Cross-sectional, retrospective and descriptive study of stroke inpatients for three years. Medical reports were reviewed to find study participants, stroke characteristics, risk factors, reasons and time of drug interruption. Results In three years, there were 360 stroke and TIA inpatients, of whom 27 (7.5%) had a history of antiplatelet or vitamin K antagonist interruption correlated with the time of the event (81% ischemic stroke, 19% TIA). The median time between antiplatelet interruption and an ischemic event was five days, and 62% of events occurred within seven days after drug suspension. For vitamin K antagonists, the average time to the ischemic event was 10.4 days (SD = 5.7), and in 67% of patients, the time between drug discontinuation and the event was 7-14 days. The most frequent reason for drug suspension was patient negligence (37%), followed by planned surgery or invasive examination (26%) and side effects, including hemorrhage (18.5%). Conclusion Antiplatelet or vitamin K antagonist suspension has a temporal relationship with the occurrence of stroke and TIA. Since these events are preventable, it is crucial that healthcare professionals convince their patients that drug withdrawal can cause serious consequences.
id ABNEURO-1_5366edbc16453a4a85030e6f84ac4f59
oai_identifier_str oai:scielo:S0004-282X2019000700456
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Stroke and transient ischemic attacks related to antiplatelet or warfarin interruptionStrokeischemic attack, transientanticoagulantscomplianceABSTRACT Patients on anticoagulant or antiplatelet therapy are often required to discontinue these medications before and during surgical or invasive procedures. In some cases, the patient stops the treatment without medical supervision. These situations may increase stroke risk. Objective To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil. Methods Cross-sectional, retrospective and descriptive study of stroke inpatients for three years. Medical reports were reviewed to find study participants, stroke characteristics, risk factors, reasons and time of drug interruption. Results In three years, there were 360 stroke and TIA inpatients, of whom 27 (7.5%) had a history of antiplatelet or vitamin K antagonist interruption correlated with the time of the event (81% ischemic stroke, 19% TIA). The median time between antiplatelet interruption and an ischemic event was five days, and 62% of events occurred within seven days after drug suspension. For vitamin K antagonists, the average time to the ischemic event was 10.4 days (SD = 5.7), and in 67% of patients, the time between drug discontinuation and the event was 7-14 days. The most frequent reason for drug suspension was patient negligence (37%), followed by planned surgery or invasive examination (26%) and side effects, including hemorrhage (18.5%). Conclusion Antiplatelet or vitamin K antagonist suspension has a temporal relationship with the occurrence of stroke and TIA. Since these events are preventable, it is crucial that healthcare professionals convince their patients that drug withdrawal can cause serious consequences.Academia Brasileira de Neurologia - ABNEURO2019-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000700456Arquivos de Neuro-Psiquiatria v.77 n.7 2019reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20190066info:eu-repo/semantics/openAccessRIZELIO,VanessaMACUCO,Andre Luiz BorbaSATO,Henry KoitiNASCIMENTO,Maria Tereza de Moraes SouzaSOUZA,Ricardo Krause Martinez deKOWACS,Pedro Andréeng2019-10-21T00:00:00Zoai:scielo:S0004-282X2019000700456Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2019-10-21T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
title Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
spellingShingle Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
RIZELIO,Vanessa
Stroke
ischemic attack, transient
anticoagulants
compliance
title_short Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
title_full Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
title_fullStr Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
title_full_unstemmed Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
title_sort Stroke and transient ischemic attacks related to antiplatelet or warfarin interruption
author RIZELIO,Vanessa
author_facet RIZELIO,Vanessa
MACUCO,Andre Luiz Borba
SATO,Henry Koiti
NASCIMENTO,Maria Tereza de Moraes Souza
SOUZA,Ricardo Krause Martinez de
KOWACS,Pedro André
author_role author
author2 MACUCO,Andre Luiz Borba
SATO,Henry Koiti
NASCIMENTO,Maria Tereza de Moraes Souza
SOUZA,Ricardo Krause Martinez de
KOWACS,Pedro André
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv RIZELIO,Vanessa
MACUCO,Andre Luiz Borba
SATO,Henry Koiti
NASCIMENTO,Maria Tereza de Moraes Souza
SOUZA,Ricardo Krause Martinez de
KOWACS,Pedro André
dc.subject.por.fl_str_mv Stroke
ischemic attack, transient
anticoagulants
compliance
topic Stroke
ischemic attack, transient
anticoagulants
compliance
description ABSTRACT Patients on anticoagulant or antiplatelet therapy are often required to discontinue these medications before and during surgical or invasive procedures. In some cases, the patient stops the treatment without medical supervision. These situations may increase stroke risk. Objective To identify the ischemic stroke and transient ischemic attack (TIA) prevalence related to length of time of discontinuation of antiplatelet or vitamin K antagonist therapy, in a group of inpatients from a specialized neurological hospital in Brazil. Methods Cross-sectional, retrospective and descriptive study of stroke inpatients for three years. Medical reports were reviewed to find study participants, stroke characteristics, risk factors, reasons and time of drug interruption. Results In three years, there were 360 stroke and TIA inpatients, of whom 27 (7.5%) had a history of antiplatelet or vitamin K antagonist interruption correlated with the time of the event (81% ischemic stroke, 19% TIA). The median time between antiplatelet interruption and an ischemic event was five days, and 62% of events occurred within seven days after drug suspension. For vitamin K antagonists, the average time to the ischemic event was 10.4 days (SD = 5.7), and in 67% of patients, the time between drug discontinuation and the event was 7-14 days. The most frequent reason for drug suspension was patient negligence (37%), followed by planned surgery or invasive examination (26%) and side effects, including hemorrhage (18.5%). Conclusion Antiplatelet or vitamin K antagonist suspension has a temporal relationship with the occurrence of stroke and TIA. Since these events are preventable, it is crucial that healthcare professionals convince their patients that drug withdrawal can cause serious consequences.
publishDate 2019
dc.date.none.fl_str_mv 2019-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000700456
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000700456
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x20190066
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.77 n.7 2019
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212785120608256